XM does not provide services to residents of the United States of America.
A
A

Ackermans

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Ackermans & Van Haaren Leads EUR 60 Million Series B Financing Round For Confo Therapeutics

BRIEF-Ackermans & Van Haaren Leads EUR 60 Million Series B Financing Round For Confo Therapeutics July 26 (Reuters) - Ackermans & Van Haaren NV ACKB.BR : ACKERMANS & VAN HAAREN NV - LEADS EUR 60 MILLION SERIES B FINANCING ROUND FOR CONFO THERAPEUTICS ACKERMANS & VAN HAAREN NV - COMMITS EUR 15 MILLION IN THE SERIES B FINANCING ROUND ACKERMANS & VAN
A

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Bunge, Aramco, Fnac Darty, Gulf Energy Development, Delen July 16 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1 930 GMT on Tuesday: * * U.S. grains merchant Bunge BG.N has offered to sell Glencore-backed GLEN.L Viterra's crush and refining plants for oilseeds in Hungary and Poland in order to secure EU antitrust approval for the $34 billion merger, a person close to the deal said.
A
A
G
G
S
P
A

Belgium's Delen Private Bank to buy smaller rival Dierickx Leys

UPDATE 1-Belgium's Delen Private Bank to buy smaller rival Dierickx Leys Delen has about 59 bln euros of assets under management Dierickx Leys has 3 bln euros in client assets Adds context from paragraph 1 By Sudip Kar-Gupta BRUSSELS, July 16 (Reuters) - Belgium's Delen Private Bank has agreed to buy smaller rival Dierickx Leys Private Bank, the companies said on Tuesday, as consolidation gathers pace in an increasingly competitive market for smaller financial companies.
A
A

Belgium's Delen Private Bank to buy smaller rival Dierickx Leys

Belgium's Delen Private Bank to buy smaller rival Dierickx Leys BRUSSELS, July 16 (Reuters) - Belgium's Delen Private Bank has agreed to buy smaller rival Dierickx Leys Private Bank, the companies said on Tuesday. Financial details of the takeover were not disclosed, but Delen Private Bank - in which Belgian holding company Ackermans & Van Haren is a shareholder - has 58.6 billion euros ($63.76 billion) of assets under management while Dierickx Leys has 3 billion euros of client assets under man
A

Bechtle AG, Centrica, Clariant AG

EUROPE RESEARCH ROUNDUP-Bechtle AG, Centrica, Clariant AG July 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bechtle AG, Centrica and Clariant AG, on Monday. HIGHLIGHTS * Akzo Nobel NV AKZO.AS : Goldman Sachs cuts to sell from neutral * Bechtle AG BC8G.DE : Exane BNP Paribas cuts to underperform from neutral * Centrica CNA.L : Berenberg raises to buy from hold * Clariant AG CLN.S : Goldman Sachs raises to buy from neutral * Fin
A
A
A
A
B
B
B
C
C
C
D
D
H
H
P
S
S
A
A
F
J

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.